Physician profile

Alice Pilram

Nurse Practitioner · Sacramento, CA

NPI 1114141645

$9,830.64

in general payments reported to CMS, 2019-2025

37 companies · $5,400 in 2025

The $5,400 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

See the full distribution for Nurse Practitioner

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$4,400.00
Food and Beverage$4,060.21
Education$11.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Soleno Therapeutics, INC. $4,469.55 2025 Vykat Xr
Boehringer Ingelheim Pharmaceuticals, INC. $346.00 2022-2025 Jardiance
Genzyme Corporation $303.86 2023-2024
Abbott Laboratories $269.54 2021-2024 Freestyle Libre 3
Amgen INC. $259.77 2022
Biogen, INC. $246.85 2024-2025 Spinraza
Neurelis, INC. $235.92 2023-2024 Valtoco
Abbvie INC. $235.31 2022-2023
Gilead Sciences, INC. $210.76 2021-2023 Epclusa
Dexcom, INC. $204.42 2021-2024 Dexcom G6 Transmitter
Ultragenyx Pharmaceutical INC. $186.72 2022-2023 Crysvita
Edwards Lifesciences Corporation $167.87 2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Neurocrine Biosciences, INC. $130.90 2022
Averitas Pharma INC. $130.00 2023 Qutenza
Inspire Medical Systems, INC. $129.69 2025 Inspire
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $127.89 2023 Xarelto
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $125.57 2023
Pharmaessentia USA Corporation $125.00 2022
Novo Nordisk INC $125.00 2023 Wegovy
Axsome Therapeutics, INC. $125.00 2024 Sunosi
Tandem Diabetes Care, INC. $125.00 2023 T:Slim X2 Insulin Pump With Control-Iq
Exact Sciences Corporation $124.03 2023 Cologuard Collection Kit
Lexicon Pharmaceuticals, INC. $123.96 2024 Inpefa
Argenx US, INC. $121.82 2025 Vyvgart
Sanofi-Aventis U.S. LLC $117.82 2025
Vertex Pharmaceuticals Incorporated $117.80 2025
Glaxosmithkline, LLC. $113.54 2022
Sage Therapeutics, LLC $111.35 2023
Acadia Pharmaceuticals INC $109.15 2023 Nuplazid
Corcept Therapeutics $103.40 2025 Korlym
Hologic Sales and Service, LLC $99.62 2024 Aptima
Pfizer INC. $90.23 2025
Ucb, INC. $87.55 2022
Teva Pharmaceuticals USA, INC. $85.89 2022
Evofem Biosciences, INC. $78.47 2024
Alk-Abello, INC $42.06 2024
Beta Bionics, INC. $23.33 2023 Ilet Bionic Pancreas

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alice Pilram

$9,830.64

in general payments reported 2019-2025

Years
2021-2025
Top company
Soleno Therapeutics, INC.
Context
The $5,400 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/11018681/alice-pilram

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.